# OnCo record nct06574347 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06574347/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06574347", "NCT06574347" ;
  schema:name "Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC."@en ;
  schema:alternateName "KYLIN-2"@en ;
  schema:description "A phase 2 trial of Vebreltinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06574347/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06574347> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-08-07" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/vebreltinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/avistone-biotechnology/> .